Theranos' big claim was they could do tests on a much smaller amount of blood. Perhaps they didn't end up doing that for Walgreens since they used externally sourced hardware, in which case they were just another test provider and if they tested out OK in ongoing QA, I don't see a problem with that from partner POV, but just from the investor POV who expected a new technology to get an edge over the competition.
IIRC they were using smaller than usual blood samples and feeding them into external testing hardware by watering down to required size. This sounds bad; but if it doesn't show up in QA - then maybe it's a legitimate advancement. If it makes testing less reliable and it doesn't show up in QA - then QA needs to be fixed. If it does show up in QA - Walgreens never should have agreed. If it does show up in QA but Walgreens never noticed - that is a problem to address.
I guess the initial deal was done on salesmanship and promises, so maybe they would have found out sooner or later.
RThey were already "found out" well before the articles were published, it's just that most VC aren't going to go out of their way to tank you, they just decline to invest
You could make a blanket statement like restaurant food isn’t very good, and on average that might be true, but anyone that knows what they’re doing would just laugh at that statement.